Biogen Inc (NASDAQ:BIIB)
| 257.86 Delayed Data As of Sep 22 |  -1.07 / -0.41%Today’s Change | 194.45 Today|||52-Week Range 319.76 | -6.88% Year-to-Date |
Latest BIIB News | Press Releases
| Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know Sep 18 / Zacks.com - Paid Partner Content | Novartis' (NVS) Sandoz Gets Rights for Stelara Biosimilar Sep 12 / Zacks.com - Paid Partner Content |
| Biogen Inc. (BIIB) Stock Moves -0.19%: What You Should Know Sep 12 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 258.93 |
| Today’s open | 259.53 |
| Day’s range | 257.08 - 260.65 |
| Volume | 46,048 |
| Average volume (3 months) | 1,030,386 |
| Market cap | $36.9B |
Data as of 3:59pm ET, 09/22/2023
Growth & Valuation
| Earnings growth (last year) | +100.92% |
| Earnings growth (this year) | -12.67% |
| Earnings growth (next 5 years) | +4.11% |
| Revenue growth (last year) | -9.32% |
| P/E ratio | 14.1 |
| Price/Sales | 4.29 |
| Price/Book | 2.74 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| MRNAModerna Inc | -0.24 | -0.24% |
| ILMNIllumina Inc | -0.91 | -0.68% |
| ---- | ||
| BMRNBiomarin Pharmaceuti... | +0.23 | +0.27% |
Data as of 4:00pm ET, 09/22/2023
Financials
| Next reporting date | October 24, 2023 |
| EPS forecast (this quarter) | $4.07 |
| Annual revenue (last year) | $9.4B |
| Annual profit (last year) | $3.0B |
| Net profit margin | 32.30% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Cambridge, Massachusetts |
Forecasts
